Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive cancer gene database aims to match tumors to future treatments

NCT ID NCT04991922

Knowledge-focused Sponsor: BostonGene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 07, 2026 · Last updated Oct 08, 2026 · Updated 1 time

Summary

Researchers are building a large registry of genomic, molecular, and clinical information from people with suspected or confirmed cancer. Participants provide tumor sequencing data and allow the team to follow their treatment and outcomes over time. The goal is to discover gene and RNA markers that may predict how different cancers respond to therapy and to link patients to future molecular-based clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the registry links specific genomic markers to cancer outcomes, it could help doctors choose treatments more precisely and connect patients to future studies that fit their tumor's biology.
What could go wrong
This is an observational registry, not a treatment trial, so it offers no direct medical benefit to participants. Findings may take years to emerge, and associations between genes and outcomes do not always translate into better care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2021

Expected to finish

Jul 2036

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects will be identified for the BIGR study from a larger group of patients undergoing BostonGene clinical testing (e.g., BostonGene Tumor Portrait TestTM).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Suspected or confirmed malignancy 2. Planned comprehensive genomic (\> 100 genes) and/or molecular analysis; or genomic and/or molecular data available from prior sequencing 3. Baseline demographics and treatment information available 4. Willingness for future contact by BIRG study personnel to provide information regarding associated cancer outcomes and treatment. 5. Signed informed consent to participate in the study. 6. Living in the United States at the time of enrollment Exclusion Criteria: Life expectancy \< 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignancy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignancy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • BostonGene

    RECRUITING

    Waltham, Massachusetts, 02453, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.